CFTR and cystic fibrosis: Currently, approximately 10% of patients with CF, who have drug-refractory missense mutations, who produce little to no CFTR protein, or who cannot tolerate CFTR modulators, are without an option of CFTR modulator therapy and still rely on symptomatic treatment (Clancy et al., 2019; Middleton et al., 2019).